CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • Contributers

Recommended Insights

Tracing The Evolution Of The Retail...

Camilla Renz, IT Director, Oriola

Effective Pharmacovigilance Driven By...

Heather Stein, MD, MPH, Vice President, Drug Safety...

3d Printed Talus Replacement

Jisun J. Lee, MS, DPM, Mica Murdoch, DPM, Ashley...

Leveraging Technology To Enhance Patient...

Michael D. Gudejko, Regional Director Surgical...

Fda Perspectives And Guidance On Software...

David Pudwill, Senior Director, Regulatory Affairs,...

Adapt to New Trends to be Competitive

Brian Thoma, PhD; Director Service Solutions North...

Using Technology to Simplify the Drug...

Xavier Flinois, President, PAREXEL Informatics

Data Science In R&D: It Is About Culture

Philippe MARC, Executive Director, Global Head of...

Tracing The Evolution Of The Retail...

Camilla Renz, IT Director, Oriola

Effective Pharmacovigilance Driven By...

Heather Stein, MD, MPH, Vice President, Drug Safety...

3d Printed Talus Replacement

Jisun J. Lee, MS, DPM, Mica Murdoch, DPM, Ashley...

Leveraging Technology To Enhance Patient...

Michael D. Gudejko, Regional Director Surgical...

Fda Perspectives And Guidance On Software...

David Pudwill, Senior Director, Regulatory Affairs,...

Adapt to New Trends to be Competitive

Brian Thoma, PhD; Director Service Solutions North...

Using Technology to Simplify the Drug...

Xavier Flinois, President, PAREXEL Informatics

Data Science In R&D: It Is About Culture

Philippe MARC, Executive Director, Global Head of...

Recent Trends and Developments in Pharmaceutical Industry

Richard Hu, Associate Director CMC, Curis [NASDAQ:CRIS]
Tweet

In our exciting and ever-changing industry, pharmaceutical and biotech companies must continue innovating not only their technologies but also the way they do business. Let’s review the top three trends that are “hot” in the eyes of a formulation scientist


The first thing that came to mind is the advancement of CRISPR/Cas9, a gene editing technology developed by Professor Zhang at MIT. Inspired by how living cells disable invading viruses, CRISPR (Clustered Regularly Short Palindromic Repeats) technology utilizes Cas9, a nuclease enzyme, to cut DNA strands at a precise location when the target gene is complexed with a guide-RNA. As a result, scientists can disable certain sequence in that gene and understand the function of that particular sequence. Sequentially, CRISPR also enables scientists to add a desired function to the gene by inserting a pre-fabricated sequence. We all know that genes define who we are as life-forms and individuals. There is no doubt that our genes have a profound effect on our health. While still in its infancy, gene editing certainly has the potential to completely transform not only our industry but our world as well. If something can finally bankrupt our social security, I think gene editing will be it.


For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game. In this new hope, scientists are developing drugs that can stimulate our own immune system to recognize and fight cancerous cells. One such advancement is the chimeric antigen receptor (CAR) T-cell technology, in which a patient’s own immune cells are removed, engineered to have the ability to recognize and attack cancerous cells, then infused back to his/her body to fight cancer. While only approved to treat limited types of cancer and may have severe side effects, the approval of Kymriah® and Yescarta® clearly represents the future of personalized medicine.


For cancer patients, chemotherapy and radiation therapy have long been the only options. Recent development of immuno-oncology has changed the game


Another trend worth mentioning in immunotherapy is the advancement of checkpoint inhibitor. These drugs are often highly targeted, highly efficient and have relatively low side effects. In recent years, antibody-based checkpoint inhibitors have dramatically improved the management of cancer. To me, developing small molecule version of such inhibitors, which are orally available and going to be much cheaper, is even more exciting.


In the foreseeable future, biopharmaceutical companies, regardless of their sizes, will continue to utilize R&D outsourcing to access innovations and expertise. According to Visiongain, the global drug discovery outsourcing market is expected to exceed $40 billion by 2026. Meanwhile, the tide of outsourcing model is certainly shifting, especially at early stage. R&D work is coming back to the States, while some companies start to run clinical trials in developing countries, often-times looking for treatment-naïve patients. I also sense a strong focus from pharmaceutical companies on partnering with academia. In the past few years, several major pharma companies moved their R&D headquarters into the most congested neighborhoods in Boston, with the intention to put their folks into the proximity of Harvard and MIT. But for God’s sake, put them in the suburb and take a subway to the “Inspiration” when needed. Haven’t they checked out the Boston morning traffic in last twenty years?


Weekly Brief

loading
Top 10 CROs - 2021
> <
  • CRO 2021

    Top Vendors

    Current Issue
  • CRO 2021

    Top Vendors

    Current Issue

Read Also

Data Science In R&D: It Is About Culture

Philippe MARC, Executive Director, Global Head of Integrated Data Science, Novartis
Data Science In R&D: It Is About Culture

Partnering With A Cdmo For Successful Late Phase Biologic Drug Product Development And Launch

Roman Mathaes, Head of Pharmaceutical Services and Cristina GrigoreCristina Grigore, at Lonza
Partnering With A Cdmo For Successful Late Phase Biologic Drug Product Development And Launch

Leading Global Cdmo, Pci Has Further Expanded Its European Biotech Packaging Capabilities With Investment Across Europe In Both The Uk And Ireland Facilities

Chris Dobbs, CEng., MIET, Head of Technical Engineering, PCI Pharma Services
Leading Global Cdmo, Pci Has Further Expanded Its European Biotech Packaging Capabilities With Investment Across Europe In Both The Uk And Ireland Facilities

Encouraging Innovation in Healthcare in a COVID - 19 World

Duncan Turner, General Partner, SOSV, Managing Director, HAX
Encouraging Innovation in Healthcare in a COVID - 19 World
How Allogeneic Stem Cell Therapies Can Transform Prospects In Inherited Retinal Diseases

How Allogeneic Stem Cell Therapies Can Transform Prospects In Inherited Retinal Diseases

Gil Carrasquinho, VP Head of Cell Therapy, Santen
Optimizing Clinical Trials: Leveraging Technology To Improve Drug Development

Optimizing Clinical Trials: Leveraging Technology To Improve Drug Development

Craig Herron, Managing Director, iSelect Fund

Addressing the Expanded Role of Patient Engagement in Clinical Research

Denis Curtin, PhD, Principal, eCOA & Patient Engagement, Signant Health
Addressing the Expanded Role of Patient Engagement in Clinical Research

The Future of Imaging and the Role of the Pathology Data Scientist in Drug Discovery

Jason Hipp, Senior Director, Head of Pathology Data Science & Innovation, Translational, AstraZeneca
The Future of Imaging and the Role of the Pathology Data Scientist in Drug Discovery
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://cro.lifesciencesreview.com/cxoinsight/recent-trends-and-developments-in-pharmaceutical-industry-nwid-334.html